Mission Statement, Vision, & Core Values (2026) of Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Founded in 2009 and headquartered in Kunshan, Jiangsu, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (listed as 688266.SS) is building a global biopharma footprint with specialty focus on oncology, hematology, and autoimmune diseases, operating three R&D centers in Kunshan, Shanghai and Thousand Oaks, California, while supporting development with two GMP-certified manufacturing plants in Kunshan (one for tablets/capsules and one for recombinant proteins); the company has secured five National Major Scientific Funds, filed approximately 335 patent applications worldwide with 128 patents issued across the USA, EU, China and other jurisdictions, and advances a pipeline spanning late clinical-stage programs alongside early clinical and pre-IND efforts under a declared mission-"Quality is life. Integrity is foundation. Innovation is fundamental"-anchored by core values of solidarity, efficiency, integrity and innovation.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) - Intro

• Established: 2009 (Kunshan, Jiangsu Province)
• Stock listing: Shanghai Stock Exchange - 688266.SS
• Therapeutic focus: oncology, hematology, autoimmune diseases
• R&D footprint: 3 centers (Kunshan, Shanghai, Thousand Oaks, CA)
• Manufacturing: 2 GMP-certified plants in Kunshan (tablets/capsules; recombinant proteins)
• National support: 5 National Major Scientific Funds granted
• Intellectual property: ~335 patent applications worldwide; 128 patents issued across USA, EU, China, others

• Scientific excellence - rigorous, evidence-based research and continuous innovation
• Patient first - prioritizing safety, efficacy, and access for patients worldwide
• Quality & compliance - adherence to GMP and global regulatory best practices
• Collaboration - cross-border R&D and strategic partnerships to accelerate development
• Integrity - transparent governance and responsible stewardship of resources

• Two GMP-certified plants in Kunshan:
  • Facility A - tablets/capsules (small molecules)
  • Facility B - recombinant protein drugs
• Quality systems aligned to support global regulatory submissions and commercial supply

• Advance oncology, hematology, and autoimmune pipelines through clinical development and lifecycle management
• Leverage international R&D (Thousand Oaks) to integrate novel biologics and translational science
• Maintain manufacturing scale-up and GMP readiness to support commercialization
• Protect and expand IP portfolio across major markets (USA, EU, China)

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) - Overview

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) pursues a mission to develop and manufacture high-quality, safe, efficacious, and affordable new medications to improve human health. The company frames its operations around solidarity, efficiency, integrity, and innovation, and advances a quality policy summarized as: 'Quality is life. Integrity is foundation. Innovation is fundamental.'

• Mission statement: develop and manufacture accessible, high-quality therapeutics that improve patient outcomes worldwide.
• Core values: solidarity, efficiency, integrity, innovation.
• Quality policy slogan: 'Quality is life. Integrity is foundation. Innovation is fundamental.'

Key R&D and innovation indicators:

The company's global R&D footprint is designed to accelerate translational research and streamline clinical development:

• Kunshan: Principal manufacturing-linked R&D and process development.
• Shanghai: Clinical development, regulatory affairs, and strategic collaborations.
• Thousand Oaks, CA (USA): Early discovery, global partnerships, and US-centric regulatory strategy.

Intellectual property and funding profile supports Zelgen's innovation pipeline and commercialization strategy:

• Approximately 335 patent applications worldwide, with 128 issued patents across major jurisdictions, underpinning product exclusivity and licensing potential.
• Five National Major Scientific Funds awarded, indicating competitive project-level support from national science funding bodies.

For more on the company's background, ownership, and how it operates financially and commercially, see: Suzhou Zelgen Biopharmaceuticals Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) - Mission Statement

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) is driven by a mission to develop innovative biologic therapies that transform care in oncology, hematology, and autoimmune diseases, and to deliver sustainable value to patients, physicians, partners, and shareholders through rigorous science, global collaboration, and disciplined commercialization.

• Advance late-stage clinical programs to regulatory approval and market entry in China and key international markets.
• Leverage a diversified pipeline spanning late clinical, early clinical, and pre-IND assets to de-risk development and accelerate time-to-market.
• Translate translational research into differentiated biologics and targeted therapies addressing high unmet medical need.
• Expand global partnerships and commercialization channels while maintaining strong local market execution in China.

Vision statement highlights:

• Become a leading pharmaceutical company in China with a global footprint focused on oncology, hematology, and autoimmune disease therapeutics.
• Pursue an international expansion strategy to access broader patient populations and strategic collaborations.
• Maintain a robust R&D engine supported by multi-site centers and major national funding awards.

Core strategic pillars and values

• Science-first innovation: prioritize rigorous preclinical and clinical validation to ensure safety and efficacy.
• Patient-centricity: design programs and access strategies that maximize patient benefit and accessibility.
• Global collaboration: build international R&D and commercialization partnerships leveraging the Kunshan, Shanghai, and Thousand Oaks hubs.
• Intellectual property strength: protect innovation with a broad patent portfolio (≈335 filings, 128 issued) to sustain competitive advantage.
• Public trust and compliance: adhere to regulatory standards and transparent governance as a STAR Market-listed company.

Operational footprint and R&D capabilities

Intellectual property and innovation metrics

• Approximately 335 patent applications demonstrate breadth of discovery and development activities.
• 128 issued patents across major jurisdictions (USA, EU, China, others) underpin freedom-to-operate and licensing leverage.
• Five National Major Scientific Funds awarded reflect recognition and support from national-level research programs.

For investor-oriented context and stakeholder insights, see: Exploring Suzhou Zelgen Biopharmaceuticals Co., Ltd. Investor Profile: Who's Buying and Why?

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) - Vision Statement

• Core Values: solidarity, efficiency, integrity, innovation.
• Quality Policy: 'Quality is life. Integrity is foundation. Innovation is fundamental.'
• Public Commitment: provide safe and efficacious products with rigorous quality systems and regulatory compliance.

• Innovation engine: approximately 335 patent applications filed globally, with 128 patents granted across the USA, EU, China and other jurisdictions.
• Scientific credibility: recipient of five National Major Scientific Funds, underscoring government-recognized research capacity.
• Global R&D footprint: three R&D centers in Kunshan, Shanghai, and Thousand Oaks, California, enabling translational research and international collaboration.
• Quality-first operations: manufacturing and quality controls aligned to the stated quality policy and applicable GMP/regulatory standards.

• Advance pipeline programs from discovery through clinical development leveraging cross-site expertise.
• Protect and commercialize innovation via a broad patent portfolio and targeted licensing/partnership strategies.
• Ensure product safety and efficacy through robust quality systems and adherence to international regulatory standards.